Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

Source :: Legal Monitor Worldwide. February 3, 2021
Publication Year :: 2021
Abstract: (GlobeNewswire) - Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the Parkinsons disease portion of the collaboration agreement, effective August [...]

Subjects :: United States. Food and Drug Administration -- Planning
Neurocrine Biosciences Inc. -- Planning
Biotechnology industry -- Planning
Gene therapy
Company business planning
Business, international
Law

Tools